AbbVie (ABBV) official guidance

AbbVie is raising its adjusted diluted EPS guidance for the full year 2026 from $13.76 - $13.96 to $13.95 - $13.99, which includes an unfavorable impact of $0.69 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter 2026.

AbbVie’s full-year 2026 adjusted diluted earnings per share guidance range, including the impact of third-quarter 2026 acquired IPR&D and milestones expense, is $13.76 - $13.96.

Turning to our financial outlook, we are updating our full-year adjusted earnings per share guidance to between $13.87 and $14.07.

As a result, AbbVie is updating its adjusted diluted EPS guidance range for the full year 2026 from $13.91 - $14.11 to $13.87 - $14.07, reflecting a change of $0.04 at the midpoint.

AbbVie’s full-year 2026 adjusted diluted earnings per share guidance range, including the impact of second-quarter 2026 acquired IPR&D and milestones expense, is $13.91 - $14.11.

Based on this strong performance, we are raising our full year adjusted earnings per share guidance by $0.12 and now expect adjusted EPS between $14.08 and $14.28.

AbbVie is raising its adjusted diluted EPS guidance for the full year 2026 from $13.96 - $14.16 to $14.08 - $14.28, which includes an unfavorable impact of $0.41 per share related to acquired IPR&D and milestones expense incurred year-to-date through the first quarter 2026. The company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the first quarter of 2026, as both cannot be reliably forecasted.

AbbVie’s full-year 2026 adjusted diluted earnings per share guidance range, including the impact of first quarter 2026 acquired IPR&D and milestones expense, is $13.96 - $14.16.

our full-year adjusted earnings per share guidance is between $14.37 and $14.57.

AbbVie is issuing its adjusted diluted EPS guidance for the full-year 2026 of $14.37 to $14.57.

Moving to the P&L for 2026, we continue to forecast full year adjusted gross margin above 84% of sales.

Moving to the P&L for 2026, we continue to forecast full-year adjusted gross margin above 84% of sales, adjusted R&D expense of approximately $9.7 billion, and adjusted SG&A expense of approximately $14.2 billion.

Moving to the P&L for 2026, we are forecasting full-year adjusted gross margin above 84% of sales, adjusted R&D expense of approximately $9.7 billion, and adjusted SG&A expense of approximately $14.2 billion.

We anticipate an adjusted operating margin ratio approaching 47% of sales.

We now anticipate an adjusted operating margin ratio of approximately 47.5% of sales, in line with our previous expectations after including the roughly 1% unfavorable impact of acquired IP R&D expense incurred through the first quarter.

We also expect an adjusted operating margin ratio of approximately 48.5%, reflecting meaningful expansion compared to 2025.

We now expect adjusted R&D expense of approximately $9.8 billion, an increase of $100 million reflecting Apogee-related pipeline investments.

Moving to the P&L for 2026, we continue to forecast full-year adjusted gross margin above 84% of sales, adjusted R&D expense of approximately $9.7 billion, and adjusted SG&A expense of approximately $14.2 billion.

Moving to the P&L for 2026, we are forecasting full-year adjusted gross margin above 84% of sales, adjusted R&D expense of approximately $9.7 billion, and adjusted SG&A expense of approximately $14.2 billion.

For aesthetics, we expect global sales of $5 billion. This includes Botox cosmetic revenue of $2.7 billion, reflecting modest market growth and relatively stable market share. And Juvéderm sales of $950 million, reflecting continued headwinds in key dermal filler markets.

We expect global immunology sales of $34.5 billion, including Skyrizi revenue of $21.5 billion, driven by market growth and share gains across the psoriatic and IBD indications, Rinvoq revenue of $10.1 billion, with growth across rheum, derm, and gastro indications, and Humira total revenue of $2.9 billion, reflecting continued biosimilar impact.

Total neuroscience revenues of $12.7 billion, an increase of $100 million, now reflecting VRAYLAR sales approaching $4.1 billion and BOTOX therapeutic sales approaching $4.2 billion.

Total neuroscience revenues of $12.6 billion, an increase of $100 million, reflecting momentum across the portfolio.

For neuroscience, we expect global sales of $12.5 billion, reflecting robust double-digit growth.

In oncology, we expect global sales of $6.5 billion, including Imbruvica revenue of $2.2 billion, reflecting competitive headwinds and the impact of lower IRA-related pricing. Venclexta sales of $3 billion, which reflects continued strong demand. And Elahere revenue of $850 million.

This includes Vraylar revenue of $4 billion, driven by continued strong prescription demand, Botox therapeutic sales of $4.1 billion, with strong performance across indications, total oral CGRP revenue of $2.9 billion, supported by market growth and share gains, and Vyalev sales of $1 billion, demonstrating the brand's impressive launch and multi-billion dollar potential.

We now expect SKYRIZI global revenues of $21.7 billion, an increase of $100 million based on momentum across psoriatic and IBD indications.

We now expect SKYRIZI global revenues of $21.6 billion, an increase of $100 million, reflecting demand growth in psoriatic and IBD indications.

We expect global immunology sales of $34.5 billion, including Skyrizi revenue of $21.5 billion, driven by market growth and share gains across the psoriatic and IBD indications, Rinvoq revenue of $10.1 billion, with growth across rheum, derm, and gastro indications, and Humira total revenue of $2.9 billion, reflecting continued biosimilar impact.

We now expect total net revenues of approximately $67.6 billion, an increase of $300 million.

We now expect total net revenues of approximately $67.3 billion, an increase of $300 million.

We expect total net revenues of approximately $67 billion, reflecting growth of 9.5%.